{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:40:15Z","timestamp":1792806015077,"version":"4.5.0"},"reference-count":125,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.canlet.2025.217771","type":"journal-article","created":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T11:08:04Z","timestamp":1746184084000},"page":"217771","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["The mechanisms and countermeasures for CAR-T cell expansion and persistence deficiency"],"prefix":"10.1016","volume":"626","author":[{"given":"Yu-Tong","family":"Bao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Jun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8139-1773","authenticated-orcid":false,"given":"Xiang-Yu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10299","key":"10.1016\/j.canlet.2025.217771_bib1","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.canlet.2025.217771_bib2","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat. Med."},{"issue":"22","key":"10.1016\/j.canlet.2025.217771_bib3","doi-asserted-by":"crossref","first-page":"6844","DOI":"10.1182\/bloodadvances.2023010364","article-title":"Early quantification of anti-CD19 CAR T cells by flow cytometry predicts response in R\/R DLBCL","volume":"7","author":"Blumenberg","year":"2023","journal-title":"Blood Adv."},{"issue":"1","key":"10.1016\/j.canlet.2025.217771_bib4","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ccell.2023.11.011","article-title":"Immune determinants of CAR-T cell expansion in solid tumor patients receiving GD2 CAR-T cell therapy","volume":"42","author":"Kaczanowska","year":"2024","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.canlet.2025.217771_bib5","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24065688","article-title":"CAR T-cell persistence correlates with improved outcome in patients with B-cell lymphoma","volume":"24","author":"Wittibschlager","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.canlet.2025.217771_bib6","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1007\/s40262-024-01413-z","article-title":"Investigating the influence of covariates on axicabtagene ciloleucel (axi-cel) kinetics in patients with non-hodgkin's lymphoma","volume":"63","author":"Chartier","year":"2024","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.canlet.2025.217771_bib7","article-title":"Chimeric antigens receptor T cell therapy improve the prognosis of pediatric acute lymphoblastic leukemia with persistent\/recurrent minimal residual disease in first complete remission","volume":"12","author":"Hu","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2025.217771_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.217264","article-title":"Consensus on the monitoring, treatment, and prevention of leukaemia relapse after allogeneic haematopoietic stem cell transplantation in China: 2024 update","volume":"605","author":"Wang","year":"2024","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.canlet.2025.217771_bib9","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/s41375-021-01351-w","article-title":"Preemptive donor-derived anti-CD19 CAR T-cell infusion showed a promising anti-leukemia effect against relapse in MRD-positive B-ALL after allogeneic hematopoietic stem cell transplantation","volume":"36","author":"Zhao","year":"2022","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.canlet.2025.217771_bib10","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.jcyt.2020.08.002","article-title":"Long-term follow-up of CD19 chimeric antigen receptor T-cell therapy for relapsed\/refractory acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation","volume":"22","author":"Chen","year":"2020","journal-title":"Cytotherapy"},{"issue":"15","key":"10.1016\/j.canlet.2025.217771_bib11","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1182\/blood-2018-11-883710","article-title":"Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy","volume":"133","author":"Hay","year":"2019","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.canlet.2025.217771_bib12","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1038\/s41375-020-0793-1","article-title":"Leukemia-induced dysfunctional TIM-3(+)CD4(+) bone marrow T cells increase risk of relapse in pediatric B-precursor ALL patients","volume":"34","author":"Blaeschke","year":"2020","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.canlet.2025.217771_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.113263","article-title":"Functional diversification and dynamics of CAR-T cells in patients with B-ALL","volume":"42","author":"Li","year":"2023","journal-title":"Cell Rep."},{"issue":"3","key":"10.1016\/j.canlet.2025.217771_bib14","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1053\/j.seminhematol.2024.04.001","article-title":"The complexities of T-cell dysfunction in chronic lymphocytic leukemia","volume":"61","author":"Camerini","year":"2024","journal-title":"Semin. Hematol."},{"issue":"21","key":"10.1016\/j.canlet.2025.217771_bib15","doi-asserted-by":"crossref","first-page":"6540","DOI":"10.1182\/bloodadvances.2023010305","article-title":"T-cell dysfunction by pseudohypoxia and autocrine purinergic signaling in chronic lymphocytic leukemia","volume":"7","author":"Montironi","year":"2023","journal-title":"Blood Adv."},{"issue":"2","key":"10.1016\/j.canlet.2025.217771_bib16","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/CJI.0000000000000193","article-title":"CD19 chimeric antigen receptor T cells from patients with chronic lymphocytic leukemia display an elevated IFN-\u03b3 production profile","volume":"41","author":"Magalhaes","year":"2018","journal-title":"J. Immunother."},{"issue":"1","key":"10.1016\/j.canlet.2025.217771_bib17","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-23589-9","article-title":"T-cell counts in peripheral blood at leukapheresis predict responses to subsequent CAR-T cell therapy","volume":"12","author":"Wada","year":"2022","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.canlet.2025.217771_bib18","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/ijc.33212","article-title":"Ibrutinib for improved chimeric antigen receptor T-cell production for chronic lymphocytic leukemia patients","volume":"148","author":"Fan","year":"2021","journal-title":"Int. J. Cancer"},{"issue":"1","key":"10.1016\/j.canlet.2025.217771_bib19","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1182\/blood.2023020554","article-title":"Ibrutinib-based therapy reinvigorates CD8+ T cells compared to chemoimmunotherapy: immune monitoring from the E1912 trial","volume":"143","author":"Papazoglou","year":"2024","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.canlet.2025.217771_bib20","doi-asserted-by":"crossref","first-page":"4633","DOI":"10.1182\/bloodadvances.2023011934","article-title":"T-cell dysfunction in CLL is mediated through expression of Siglec-10 ligands CD24 and CD52 on CLL cells","volume":"8","author":"van Bruggen","year":"2024","journal-title":"Blood Adv."},{"issue":"9","key":"10.1016\/j.canlet.2025.217771_bib21","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1158\/2767-9764.CRC-22-0200","article-title":"Enhanced costimulatory signaling improves CAR T-cell effector responses in CLL","volume":"2","author":"Collins","year":"2022","journal-title":"Cancer Res. Commun."},{"key":"10.1016\/j.canlet.2025.217771_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215949","article-title":"BCMA-targeting chimeric antigen receptor T-cell therapy for multiple myeloma","volume":"553","author":"Yang","year":"2023","journal-title":"Cancer Lett."},{"issue":"22","key":"10.1016\/j.canlet.2025.217771_bib23","doi-asserted-by":"crossref","first-page":"5873","DOI":"10.1182\/bloodadvances.2022007217","article-title":"Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level","volume":"6","author":"Schinke","year":"2022","journal-title":"Blood Adv."},{"issue":"8","key":"10.1016\/j.canlet.2025.217771_bib24","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1038\/leu.2016.84","article-title":"Multiple myeloma causes clonal T-cell immunosenescence: identification of potential novel targets for promoting tumour immunity and implications for checkpoint blockade","volume":"30","author":"Suen","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2025.217771_bib25","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.3389\/fimmu.2020.02153","article-title":"Conventional treatment for multiple myeloma drives premature aging phenotypes and metabolic dysfunction in T cells","volume":"11","author":"Cooke","year":"2020","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.canlet.2025.217771_bib26","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s13045-016-0345-3","article-title":"T cells in multiple myeloma display features of exhaustion and senescence at the tumor site","volume":"9","author":"Zelle-Rieser","year":"2016","journal-title":"J. Hematol. Oncol."},{"issue":"18","key":"10.1016\/j.canlet.2025.217771_bib27","doi-asserted-by":"crossref","first-page":"4201","DOI":"10.1158\/1078-0432.CCR-24-0352","article-title":"Reconstitution of the multiple myeloma microenvironment following lymphodepletion with BCMA CAR-T therapy","volume":"30","author":"Yang","year":"2024","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.canlet.2025.217771_bib28","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/s41591-022-01726-1","article-title":"PSMA-targeting TGF\u03b2-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial","volume":"28","author":"Narayan","year":"2022","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.canlet.2025.217771_bib29","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41571-023-00832-4","article-title":"CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn","volume":"21","author":"Albelda","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.217771_bib30","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.omto.2021.06.006","article-title":"Imaging CAR T-cell kinetics in solid tumors: translational implications","volume":"22","author":"Skovgard","year":"2021","journal-title":"Mol. Ther. Oncolytics"},{"issue":"1","key":"10.1016\/j.canlet.2025.217771_bib31","doi-asserted-by":"crossref","first-page":"5110","DOI":"10.1038\/s41467-023-40850-5","article-title":"Desmoplastic stroma restricts T cell extravasation and mediates immune exclusion and immunosuppression in solid tumors","volume":"14","author":"Xiao","year":"2023","journal-title":"Nat. Commun."},{"issue":"19","key":"10.1016\/j.canlet.2025.217771_bib32","doi-asserted-by":"crossref","first-page":"4434","DOI":"10.1158\/1078-0432.CCR-23-3298","article-title":"Redirecting B7-H3.CAR T cells to chemokines expressed in osteosarcoma enhances homing and antitumor activity in preclinical models","volume":"30","author":"Talbot","year":"2024","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.canlet.2025.217771_bib33","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1016\/j.ymthe.2019.07.015","article-title":"Phase I study of lentiviral-transduced chimeric antigen receptor-modified T cells recognizing mesothelin in advanced solid cancers","volume":"27","author":"Haas","year":"2019","journal-title":"Mol. Ther."},{"issue":"3","key":"10.1016\/j.canlet.2025.217771_bib34","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.ccell.2023.01.009","article-title":"Metabolic programming and immune suppression in the tumor microenvironment","volume":"41","author":"Arner","year":"2023","journal-title":"Cancer Cell"},{"issue":"399","key":"10.1016\/j.canlet.2025.217771_bib35","article-title":"A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma","volume":"9","author":"O'Rourke","year":"2017","journal-title":"Sci. Transl. Med."},{"issue":"9","key":"10.1016\/j.canlet.2025.217771_bib36","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1158\/2159-8290.CD-20-1677","article-title":"Integrative bulk and single-cell profiling of premanufacture T-cell populations reveals factors mediating long-term persistence of CAR T-cell therapy","volume":"11","author":"Chen","year":"2021","journal-title":"Cancer Discov."},{"issue":"6","key":"10.1016\/j.canlet.2025.217771_bib37","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/s43018-021-00207-7","article-title":"Clonal expansion of T memory stem cells determines early anti-leukemic responses and long-term CAR T cell persistence in patients","volume":"2","author":"Biasco","year":"2021","journal-title":"Nat. Cancer"},{"issue":"5","key":"10.1016\/j.canlet.2025.217771_bib38","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.immuni.2011.09.016","article-title":"A critical role for STAT3 transcription factor signaling in the development and maintenance of human T cell memory","volume":"35","author":"Siegel","year":"2011","journal-title":"Immunity"},{"issue":"5","key":"10.1016\/j.canlet.2025.217771_bib39","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23052878","article-title":"STAT3 role in T-cell memory formation","volume":"23","author":"Kaminskiy","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"8010","key":"10.1016\/j.canlet.2025.217771_bib40","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41586-024-07300-8","article-title":"FOXO1 is a master regulator of memory programming in CAR T cells","volume":"629","author":"Doan","year":"2024","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.canlet.2025.217771_bib41","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1038\/s41591-020-1061-7","article-title":"Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas","volume":"26","author":"Deng","year":"2020","journal-title":"Nat. Med."},{"issue":"9","key":"10.1016\/j.canlet.2025.217771_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.110079","article-title":"CD19-CAR T cells undergo exhaustion DNA methylation programming in patients with acute lymphoblastic leukemia","volume":"37","author":"Zebley","year":"2021","journal-title":"Cell Rep."},{"issue":"9","key":"10.1016\/j.canlet.2025.217771_bib43","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1038\/s41375-023-01966-1","article-title":"Culture expansion of CAR T cells results in aberrant DNA methylation that is associated with adverse clinical outcome","volume":"37","author":"Salz","year":"2023","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.canlet.2025.217771_bib44","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.immuni.2020.04.014","article-title":"Developmental relationships of four exhausted CD8(+) T cell subsets reveals underlying transcriptional and epigenetic landscape control mechanisms","volume":"52","author":"Beltra","year":"2020","journal-title":"Immunity"},{"issue":"25","key":"10.1016\/j.canlet.2025.217771_bib45","doi-asserted-by":"crossref","first-page":"12410","DOI":"10.1073\/pnas.1905675116","article-title":"TOX and TOX2 transcription factors cooperate with NR4A transcription factors to impose CD8(+) T cell exhaustion","volume":"116","author":"Seo","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"7749","key":"10.1016\/j.canlet.2025.217771_bib46","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/s41586-019-0985-x","article-title":"NR4A transcription factors limit CAR T cell function in solid tumours","volume":"567","author":"Chen","year":"2019","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.canlet.2025.217771_bib47","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1038\/s41590-021-00964-8","article-title":"BATF and IRF4 cooperate to counter exhaustion in tumor-infiltrating CAR T cells","volume":"22","author":"Seo","year":"2021","journal-title":"Nat. Immunol."},{"issue":"8","key":"10.1016\/j.canlet.2025.217771_bib48","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1038\/s41590-021-00978-2","article-title":"BATF targets T cell exhaustion for termination","volume":"22","author":"Boi","year":"2021","journal-title":"Nat. Immunol."},{"issue":"11","key":"10.1016\/j.canlet.2025.217771_bib49","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/j.ccell.2022.09.013","article-title":"Depletion of BATF in CAR-T cells enhances antitumor activity by inducing resistance against exhaustion and formation of central memory cells","volume":"40","author":"Zhang","year":"2022","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.canlet.2025.217771_bib50","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/s41591-021-01326-5","article-title":"Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cells","volume":"27","author":"Singh","year":"2021","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.canlet.2025.217771_bib51","doi-asserted-by":"crossref","first-page":"4732","DOI":"10.1038\/s41467-023-40303-z","article-title":"Complementarity-determining region clustering may cause CAR-T cell dysfunction","volume":"14","author":"Sar\u00e9n","year":"2023","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.canlet.2025.217771_bib52","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41422-023-00789-0","article-title":"Tuning charge density of chimeric antigen receptor optimizes tonic signaling and CAR-T cell fitness","volume":"33","author":"Chen","year":"2023","journal-title":"Cell Res."},{"issue":"4","key":"10.1016\/j.canlet.2025.217771_bib53","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1158\/2326-6066.CIR-20-0451","article-title":"Modifications to the framework regions eliminate chimeric antigen receptor tonic signaling","volume":"9","author":"Landoni","year":"2021","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.canlet.2025.217771_bib54","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.omto.2020.06.016","article-title":"Efficacy and safety of CD28- or 4-1BB-based CD19 CAR-T cells in B cell acute lymphoblastic leukemia","volume":"18","author":"Zhao","year":"2020","journal-title":"Mol. Ther. Oncolytics"},{"issue":"3","key":"10.1016\/j.canlet.2025.217771_bib55","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1182\/bloodadvances.2019000525","article-title":"Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed\/refractory DLBCL","volume":"4","author":"Awasthi","year":"2020","journal-title":"Blood Adv."},{"issue":"19","key":"10.1016\/j.canlet.2025.217771_bib56","doi-asserted-by":"crossref","first-page":"9543","DOI":"10.1073\/pnas.1819745116","article-title":"Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed\/refractory multiple myeloma","volume":"116","author":"Xu","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA."},{"issue":"6","key":"10.1016\/j.canlet.2025.217771_bib57","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J. Clin. Investig."},{"issue":"1","key":"10.1016\/j.canlet.2025.217771_bib58","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/s41392-021-00670-9","article-title":"Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer","volume":"6","author":"Li","year":"2021","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"19","key":"10.1016\/j.canlet.2025.217771_bib59","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1182\/blood.2020007445","article-title":"Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma","volume":"137","author":"Jain","year":"2021","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.canlet.2025.217771_bib60","doi-asserted-by":"crossref","DOI":"10.3390\/cells10102655","article-title":"Regulation of T Cells in cancer by nitric oxide","volume":"10","author":"Navasardyan","year":"2021","journal-title":"Cells"},{"issue":"9","key":"10.1016\/j.canlet.2025.217771_bib61","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1469594","article-title":"VISTA is highly expressed on MDSCs and mediates an inhibition of T cell response in patients with AML","volume":"7","author":"Wang","year":"2018","journal-title":"OncoImmunology"},{"issue":"11","key":"10.1016\/j.canlet.2025.217771_bib62","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007802","article-title":"MDSCs-derived GPR84 induces CD8(+) T-cell senescence via p53 activation to suppress the antitumor response","volume":"11","author":"Liu","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2025.217771_bib63","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1146\/annurev.immunol.25.022106.141623","article-title":"Regulatory T cells: mechanisms of differentiation and function","volume":"30","author":"Josefowicz","year":"2012","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.canlet.2025.217771_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.107742","article-title":"CD4(+)CD25(+)CD127(low) regulatory T cells associated with the effect of CD19 CAR-T therapy for relapsed\/refractory B-cell acute lymphoblastic leukemia","volume":"96","author":"Pan","year":"2021","journal-title":"Int. Immunopharmacol."},{"issue":"1","key":"10.1016\/j.canlet.2025.217771_bib65","doi-asserted-by":"crossref","first-page":"5928","DOI":"10.1038\/s41467-020-19774-x","article-title":"Influence of patient characteristics on chimeric antigen receptor T cell therapy in B-cell acute lymphoblastic leukemia","volume":"11","author":"An","year":"2020","journal-title":"Nat. Commun."},{"issue":"9","key":"10.1016\/j.canlet.2025.217771_bib66","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1038\/s41591-022-01959-0","article-title":"Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma","volume":"28","author":"Haradhvala","year":"2022","journal-title":"Nat. Med."},{"issue":"9","key":"10.1016\/j.canlet.2025.217771_bib67","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1038\/s41591-022-01960-7","article-title":"Post-infusion CAR T(Reg) cells identify patients resistant to CD19-CAR therapy","volume":"28","author":"Good","year":"2022","journal-title":"Nat. Med."},{"issue":"12","key":"10.1016\/j.canlet.2025.217771_bib68","doi-asserted-by":"crossref","DOI":"10.3390\/biom13121701","article-title":"Engagement of mesenchymal stromal cells in the remodeling of the bone marrow microenvironment in hematological cancers","volume":"13","author":"Giallongo","year":"2023","journal-title":"Biomolecules"},{"issue":"1","key":"10.1016\/j.canlet.2025.217771_bib69","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s00262-023-03594-1","article-title":"Bone marrow-derived mesenchymal stromal cells obstruct AML-targeting CD8(+) clonal effector and CAR T-cell function while promoting a senescence-associated phenotype","volume":"73","author":"Towers","year":"2024","journal-title":"Cancer Immunol. Immunother."},{"issue":"38","key":"10.1016\/j.canlet.2025.217771_bib70","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adg3919","article-title":"Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansion","volume":"9","author":"Rejeski","year":"2023","journal-title":"Sci. Adv."},{"issue":"19","key":"10.1016\/j.canlet.2025.217771_bib71","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1182\/bloodadvances.2020002394","article-title":"Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Locke","year":"2020","journal-title":"Blood Adv."},{"issue":"12","key":"10.1016\/j.canlet.2025.217771_bib72","doi-asserted-by":"crossref","first-page":"3697","DOI":"10.1038\/s41591-024-03271-5","article-title":"Cytokine-mediated CAR T therapy resistance in AML","volume":"30","author":"Bhagwat","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2025.217771_bib73","first-page":"1","article-title":"Impact of pre-infusion disease burden on outcomes in pediatric relapsed\/refractory B-cell lymphoblastic leukemia following anti-CD19 CAR T-cell therapy","author":"Shang","year":"2024","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.canlet.2025.217771_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217542","article-title":"Translational study of the regulatory mechanism by which immune synapses enhance immune cell function","volume":"614","author":"Li","year":"2025","journal-title":"Cancer Lett."},{"issue":"2","key":"10.1016\/j.canlet.2025.217771_bib75","doi-asserted-by":"crossref","DOI":"10.1111\/sji.13273","article-title":"The role of bone marrow microenvironment on CAR-T efficacy in haematologic malignancies","volume":"98","author":"Gao","year":"2023","journal-title":"Scand. J. Immunol."},{"issue":"8","key":"10.1016\/j.canlet.2025.217771_bib76","doi-asserted-by":"crossref","DOI":"10.1002\/hem3.142","article-title":"PD-L1(+) macrophage and tumor cell abundance and proximity to T cells in the pretreatment large B-cell lymphoma microenvironment impact CD19 CAR-T cell immunotherapy efficacy","volume":"8","author":"Hirayama","year":"2024","journal-title":"Hemasphere"},{"issue":"4","key":"10.1016\/j.canlet.2025.217771_bib77","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.cell.2019.07.019","article-title":"Opposing functions of interferon coordinate adaptive and innate immune responses to cancer immune checkpoint blockade","volume":"178","author":"Benci","year":"2019","journal-title":"Cell"},{"issue":"23","key":"10.1016\/j.canlet.2025.217771_bib78","doi-asserted-by":"crossref","first-page":"6995","DOI":"10.1158\/1078-0432.CCR-19-0101","article-title":"Clinical efficacy and tumor microenvironment influence in a dose-escalation study of anti-CD19 chimeric antigen receptor T cells in refractory B-cell non-hodgkin's lymphoma","volume":"25","author":"Yan","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.canlet.2025.217771_bib79","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s12943-024-02079-8","article-title":"Reshaping the tumor immune microenvironment to improve CAR-T cell-based cancer immunotherapy","volume":"23","author":"Xia","year":"2024","journal-title":"Mol. Cancer"},{"issue":"4","key":"10.1016\/j.canlet.2025.217771_bib80","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.133977","article-title":"TGF-\u03b2 inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors","volume":"5","author":"Tang","year":"2020","journal-title":"JCI Insight"},{"issue":"7","key":"10.1016\/j.canlet.2025.217771_bib81","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/j.ymthe.2018.05.003","article-title":"Dominant-negative TGF-\u03b2 receptor enhances PSMA-targeted human CAR T cell proliferation and augments prostate cancer eradication","volume":"26","author":"Kloss","year":"2018","journal-title":"Mol. Ther."},{"issue":"3","key":"10.1016\/j.canlet.2025.217771_bib82","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.stem.2024.02.003","article-title":"From suppressor to enhancer: IL-10's alternative role in CAR-T cell therapies against solid tumors","volume":"31","author":"Huang","year":"2024","journal-title":"Cell Stem Cell"},{"issue":"25","key":"10.1016\/j.canlet.2025.217771_bib83","doi-asserted-by":"crossref","first-page":"3905","DOI":"10.1182\/blood-2015-01-621474","article-title":"Tumor indoleamine 2,3-dioxygenase (Ido) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs","volume":"125","author":"Ninomiya","year":"2015","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.canlet.2025.217771_bib84","first-page":"132","article-title":"CAR T cell manufacturing from naive\/stem memory T lymphocytes enhances antitumor responses while curtailing cytokine release syndrome","author":"Arcangeli","year":"2022","journal-title":"J. Clin. Investig."},{"issue":"690","key":"10.1016\/j.canlet.2025.217771_bib85","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abk1900","article-title":"T(STEM)-like CAR-T cells exhibit improved persistence and tumor control compared with conventional CAR-T cells in preclinical models","volume":"15","author":"Meyran","year":"2023","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.canlet.2025.217771_bib86","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1172\/JCI81217","article-title":"Memory T cell-driven differentiation of naive cells impairs adoptive immunotherapy","volume":"126","author":"Klebanoff","year":"2016","journal-title":"J. Clin. Investig."},{"issue":"4","key":"10.1016\/j.canlet.2025.217771_bib87","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1182\/blood-2012-05-431718","article-title":"IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors","volume":"121","author":"Cieri","year":"2013","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.canlet.2025.217771_bib88","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1186\/s40425-019-0804-9","article-title":"Expanding CAR T cells in human platelet lysate renders T cells with in vivo longevity","volume":"7","author":"Torres","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2025.217771_bib89","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s40425-017-0227-4","article-title":"Ex vivo Akt inhibition promotes the generation of potent CD19CAR T cells for adoptive immunotherapy","volume":"5","author":"Urak","year":"2017","journal-title":"J. Immunother. Cancer"},{"issue":"5","key":"10.1016\/j.canlet.2025.217771_bib90","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/s41375-017-0008-6","article-title":"PI3K orchestration of the in vivo persistence of chimeric antigen receptor-modified T cells","volume":"32","author":"Zheng","year":"2018","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.canlet.2025.217771_bib91","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s11060-019-03311-y","article-title":"Shortened ex vivo manufacturing time of EGFRvIII-specific chimeric antigen receptor (CAR) T cells reduces immune exhaustion and enhances antiglioma therapeutic function","volume":"145","author":"Caruso","year":"2019","journal-title":"J. Neuro Oncol."},{"issue":"2","key":"10.1016\/j.canlet.2025.217771_bib92","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41551-021-00842-6","article-title":"Rapid manufacturing of non-activated potent CAR T cells","volume":"6","author":"Ghassemi","year":"2022","journal-title":"Nat. Biomed. Eng."},{"issue":"670","key":"10.1016\/j.canlet.2025.217771_bib93","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abn7336","article-title":"BLIMP1 and NR4A3 transcription factors reciprocally regulate antitumor CAR T cell stemness and exhaustion","volume":"14","author":"Jung","year":"2022","journal-title":"Sci. Transl. Med."},{"issue":"7786","key":"10.1016\/j.canlet.2025.217771_bib94","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41586-019-1805-z","article-title":"c-Jun overexpression in CAR T cells induces exhaustion resistance","volume":"576","author":"Lynn","year":"2019","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.canlet.2025.217771_bib95","doi-asserted-by":"crossref","first-page":"6155","DOI":"10.1038\/s41467-024-50485-9","article-title":"C-JUN overexpressing CAR-T cells in acute myeloid leukemia: preclinical characterization and phase I trial","volume":"15","author":"Zuo","year":"2024","journal-title":"Nat. Commun."},{"issue":"620","key":"10.1016\/j.canlet.2025.217771_bib96","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abh0272","article-title":"Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity","volume":"13","author":"Prinzing","year":"2021","journal-title":"Sci. Transl. Med."},{"issue":"7951","key":"10.1016\/j.canlet.2025.217771_bib97","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/s41586-022-05692-z","article-title":"TET2 guards against unchecked BATF3-induced CAR T cell expansion","volume":"615","author":"Jain","year":"2023","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.canlet.2025.217771_bib98","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1158\/2159-8290.CD-22-1319","article-title":"Disruption of SUV39H1-mediated H3K9 methylation sustains CAR T-cell function","volume":"14","author":"Jain","year":"2024","journal-title":"Cancer Discov."},{"issue":"2","key":"10.1016\/j.canlet.2025.217771_bib99","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41591-019-0737-3","article-title":"Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma","volume":"26","author":"Brudno","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2025.217771_bib100","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215762","article-title":"CD147-specific chimeric antigen receptor T cells effectively inhibit T cell acute lymphoblastic leukemia","volume":"542","author":"Zheng","year":"2022","journal-title":"Cancer Lett."},{"issue":"5","key":"10.1016\/j.canlet.2025.217771_bib101","first-page":"945","article-title":"Antitumor activity of NKG2D CAR-T cells against human colorectal cancer cells in vitro and in vivo","volume":"9","author":"Deng","year":"2019","journal-title":"Am. J. Cancer Res."},{"issue":"11","key":"10.1016\/j.canlet.2025.217771_bib102","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/j.jcyt.2024.06.010","article-title":"Hu8F4-CAR T cells with mutated Fc spacer segment improve target specificity and mediate anti-leukemia activity in vivo","volume":"26","author":"He","year":"2024","journal-title":"Cytotherapy"},{"issue":"2","key":"10.1016\/j.canlet.2025.217771_bib103","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1002\/hep.32279","article-title":"Novel low-avidity glypican-3 specific CARTs resist exhaustion and mediate durable antitumor effects against HCC","volume":"76","author":"Caraballo","year":"2022","journal-title":"Hepatology"},{"issue":"7750","key":"10.1016\/j.canlet.2025.217771_bib104","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41586-019-1054-1","article-title":"CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape","volume":"568","author":"Hamieh","year":"2019","journal-title":"Nature"},{"issue":"81","key":"10.1016\/j.canlet.2025.217771_bib105","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.adf1426","article-title":"CD19 CAR antigen engagement mechanisms and affinity tuning","volume":"8","author":"He","year":"2023","journal-title":"Sci. Immunol."},{"issue":"11","key":"10.1016\/j.canlet.2025.217771_bib106","doi-asserted-by":"crossref","first-page":"6545","DOI":"10.4049\/jimmunol.1001867","article-title":"Reduced functional avidity promotes central and effector memory CD4 T cell responses to tumor-associated antigens","volume":"185","author":"Caserta","year":"2010","journal-title":"J. Immunol."},{"issue":"9","key":"10.1016\/j.canlet.2025.217771_bib107","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1038\/s41591-019-0549-5","article-title":"Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR","volume":"25","author":"Ghorashian","year":"2019","journal-title":"Nat. Med."},{"issue":"23","key":"10.1016\/j.canlet.2025.217771_bib108","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2406526","article-title":"Obecabtagene autoleucel in adults with B-cell acute lymphoblastic leukemia","volume":"391","author":"Roddie","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.canlet.2025.217771_bib109","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.it.2004.12.003","article-title":"Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy","volume":"26","author":"Klebanoff","year":"2005","journal-title":"Trends Immunol."},{"issue":"7","key":"10.1016\/j.canlet.2025.217771_bib110","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1016\/j.ymthe.2021.02.024","article-title":"Pre-conditioning modifies the TME to enhance solid tumor CAR T cell efficacy and endogenous protective immunity","volume":"29","author":"Murad","year":"2021","journal-title":"Mol. Ther."},{"issue":"16","key":"10.1016\/j.canlet.2025.217771_bib111","doi-asserted-by":"crossref","DOI":"10.1097\/CM9.0000000000002764","article-title":"Bridging chimeric antigen receptor T-cell before transplantation improves prognosis of relapsed\/refractory B-cell acute lymphoblastic leukemia","volume":"136","author":"Zhao","year":"2023","journal-title":"Chin. Med. J."},{"issue":"1","key":"10.1016\/j.canlet.2025.217771_bib112","doi-asserted-by":"crossref","first-page":"5346","DOI":"10.1038\/s41467-023-40852-3","article-title":"Low-dose carboplatin modifies the tumor microenvironment to augment CAR T cell efficacy in human prostate cancer models","volume":"14","author":"Porter","year":"2023","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.canlet.2025.217771_bib113","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004400","article-title":"PD-L1 blockade restores CAR T cell activity through IFN-\u03b3-regulation of CD163+ M2 macrophages","volume":"10","author":"Yamaguchi","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.canlet.2025.217771_bib114","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ymthe.2020.09.034","article-title":"Olaparib suppresses MDSC recruitment via SDF1\u03b1\/CXCR4 Axis to improve the anti-tumor efficacy of CAR-T cells on breast cancer in mice","volume":"29","author":"Sun","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.canlet.2025.217771_bib115","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2023.101663","article-title":"GD2 CAR-T cells in combination with Nivolumab exhibit enhanced antitumor efficacy","volume":"32","author":"Zhang","year":"2023","journal-title":"Transl. Oncol."},{"issue":"7","key":"10.1016\/j.canlet.2025.217771_bib116","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1182\/blood.2021012634","article-title":"Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy","volume":"139","author":"Chong","year":"2022","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.canlet.2025.217771_bib117","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1016\/j.celrep.2018.04.051","article-title":"Engineered tumor-targeted T cells mediate enhanced anti-tumor efficacy both directly and through activation of the endogenous immune system","volume":"23","author":"Avanzi","year":"2018","journal-title":"Cell Rep."},{"issue":"9","key":"10.1016\/j.canlet.2025.217771_bib118","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1158\/1078-0432.CCR-18-1811","article-title":"Eradication of neuroblastoma by T cells redirected with an optimized GD2-specific chimeric antigen receptor and interleukin-15","volume":"25","author":"Chen","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.canlet.2025.217771_bib119","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/leu.2014.215","article-title":"IL-12-secreting CD19-targeted cord blood-derived T cells for the immunotherapy of B-cell acute lymphoblastic leukemia","volume":"29","author":"Pegram","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2025.217771_bib120","doi-asserted-by":"crossref","first-page":"803","DOI":"10.3389\/fcell.2020.00803","article-title":"Augmenting the effectiveness of CAR-T cells by enhanced self-delivery of PD-1-neutralizing scFv","volume":"8","author":"Ping","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.canlet.2025.217771_bib121","doi-asserted-by":"crossref","first-page":"8893","DOI":"10.2147\/CMAR.S260915","article-title":"EGLIF-CAR-T cells secreting PD-1 blocking antibodies significantly mediate the elimination of gastric cancer","volume":"12","author":"Zhou","year":"2020","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.canlet.2025.217771_bib122","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216660","article-title":"Delivery of CD47-SIRP\u03b1 checkpoint blocker by BCMA-directed UCAR-T cells enhances antitumor efficacy in multiple myeloma","volume":"585","author":"Lu","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2025.217771_bib123","article-title":"Construction and characterization of a novel secreted MsC-CAR-T cell in solid tumors","volume":"611","author":"Mao","year":"2024","journal-title":"Cancer Lett."},{"issue":"10","key":"10.1016\/j.canlet.2025.217771_bib124","article-title":"Preclinical development of a chimeric antigen receptor T cell therapy targeting FGFR4 in rhabdomyosarcoma","volume":"4","author":"Tian","year":"2023","journal-title":"Cell Rep. Med."},{"issue":"9","key":"10.1016\/j.canlet.2025.217771_bib125","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.jcyt.2021.05.008","article-title":"Anti-tumor effects of vascular endothelial growth factor\/vascular endothelial growth factor receptor binding domain-modified chimeric antigen receptor T cells","volume":"23","author":"Xing","year":"2021","journal-title":"Cytotherapy"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383525003374?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383525003374?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T23:01:28Z","timestamp":1760742088000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383525003374"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":125,"alternative-id":["S0304383525003374"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2025.217771","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The mechanisms and countermeasures for CAR-T cell expansion and persistence deficiency","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2025.217771","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"217771"}}